Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Cash from Operations: 2017-2025

Historic Cash from Operations for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$40.6 million.

  • Cidara Therapeutics' Cash from Operations fell 10.68% to -$40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.9 million, marking a year-over-year increase of 16.83%. This contributed to the annual value of -$176.5 million for FY2024, which is 686.97% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Cash from Operations of -$40.6 million as of Q3 2025, which was up 0.84% from -$41.0 million recorded in Q2 2025.
  • Cidara Therapeutics' Cash from Operations' 5-year high stood at $28.0 million during Q3 2022, with a 5-year trough of -$103.8 million in Q2 2024.
  • For the 3-year period, Cidara Therapeutics' Cash from Operations averaged around -$27.5 million, with its median value being -$21.9 million (2025).
  • In the last 5 years, Cidara Therapeutics' Cash from Operations skyrocketed by 333.65% in 2022 and then plummeted by 3,777.53% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Cash from Operations (Quarterly) stood at -$14.9 million in 2021, then slumped by 40.89% to -$21.0 million in 2022, then skyrocketed by 39.42% to -$12.7 million in 2023, then tumbled by 131.21% to -$29.4 million in 2024, then dropped by 10.68% to -$40.6 million in 2025.
  • Its last three reported values are -$40.6 million in Q3 2025, -$41.0 million for Q2 2025, and -$21.9 million during Q1 2025.